NasdaqGS:IBRXBiotechs
Did ImmunityBio’s (IBRX) New Chemotherapy‑Free CAR‑NK Phase 2 Trial Just Redefine Its Investment Narrative?
ImmunityBio recently launched ResQ215B, a Phase 2 outpatient trial testing a chemotherapy-free, lymphodepletion-free combination of off-the-shelf CD19-targeted NK cells, ANKTIVA, and rituximab in patients with indolent B-cell non-Hodgkin lymphoma, including Waldenström’s Macroglobulinemia.
This regimen builds on early Phase 1 data showing durable disease control without hospitalization or lymphodepleting chemotherapy, aiming to enhance immune-driven tumor clearance through IL-15...